Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced its commitment to improving healthcare access for individuals affected by systemic lupus erythematosus (SLE) and lupus nephritis (LN), coinciding with World Lupus Day. The company is sponsoring grants to establish patient navigator programs aimed at underserved communities, particularly Black, Asian, and Hispanic populations disproportionately affected by LN. As the COVID-19 pandemic has hindered healthcare access, these programs are crucial for connecting patients to necessary resources and education. Organizations can apply for grants until June 1, 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the publication of Phase 3 AURORA 1 study results for LUPKYNIS (voclosporin) in treating lupus nephritis (LN). The study, published in The Lancet, demonstrated that LUPKYNIS combined with mycophenolate mofetil (MMF) and low-dose corticosteroids achieved a complete renal response rate of 41% at 52 weeks, significantly outpacing the 23% in the control group. Additionally, LUPKYNIS was well-tolerated, showing a comparable safety profile to the standard treatment. FDA approved LUPKYNIS in January 2021.

Aurinia Pharmaceuticals reported its financial results for Q1 2021, with revenues of $0.9 million attributed to the launch of LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis. The company experienced a net loss of $50.4 million or $0.40 per share, up from a $25.9 million loss in Q1 2020. Operating cash decreased to $360.9 million due to commercial infrastructure investments. Aurinia anticipates improved market access as healthcare facilities reopen. Upcoming milestones include EMA filing and new clinical trials.

Aurinia Pharmaceuticals will release its Q1 2021 financial results on May 6, 2021, after market closure. A conference call is scheduled for the same day at 5:00 p.m. EDT to discuss the results and provide a business update. The call can be accessed via dial-in or through an audio webcast available on the company's website. Aurinia focuses on serious diseases, having introduced LUPKYNIS™, the first FDA-approved oral therapy for adult patients with active lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation of its executive management team in a fireside chat at the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 2:30 p.m. ET. Interested individuals can access the live audio webcast through the 'News/Events' section on Aurinia's corporate website. A replay will also be available. Aurinia focuses on therapies for serious diseases, having launched LUPKYNIS™ (voclosporin), the first FDA-approved oral treatment for active lupus nephritis in adults.

Aurinia Pharmaceuticals (NASDAQ: AUPH) presented new data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS (voclosporin) for lupus nephritis (LN) at the NKF 2021 Spring Clinical Meetings. The pooled data from 532 patients showed significant treatment benefits in complete renal response (CRR) for LUPKYNIS compared to placebo across various biopsy class subgroups. LUPKYNIS, the first FDA-approved oral treatment for adult LN, offers a dual mechanism of action and is designed to improve outcomes in patients with this serious condition.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced a favorable assessment of LUPKYNIS™ (voclosporin) by the Institute for Clinical and Economic Review (ICER). The report, dated March 12, 2021, states LUPKYNIS is a cost-effective treatment for lupus nephritis (LN), particularly for African American patients. In clinical trials, LUPKYNIS nearly doubled complete response rates compared to standard therapy. ICER highlighted the drug's potential to reduce healthcare disparities. CEO Peter Greenleaf expressed optimism about LUPKYNIS' real-world value for patients and the healthcare system.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in three upcoming investor conferences. The events include the Cowen 41^st Annual Healthcare Conference on March 4, 2021, at 2:10 p.m. ET, the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer’s 31^st Annual Healthcare Conference on March 17, 2021, at 10:40 a.m. ET. Interested investors can access the live webcasts through the 'Investors' section on Aurinia's website. Aurinia specializes in therapies for serious diseases, notably the FDA-approved LUPKYNIS™ for lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported its financial results for Q4 and the year ended December 31, 2020, showing significant growth following the FDA approval and launch of LUPKYNIS for lupus nephritis. Revenues surged to $50.1 million, primarily due to a $50 million upfront payment from Otsuka. Despite a net loss of $102.7 million for the year, the company holds $423 million in cash and investments, sufficient to support operations into 2023. R&D expenses decreased to $50.3 million, while corporate expenses surged due to commercial infrastructure buildup.